These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

306 related articles for article (PubMed ID: 16978829)

  • 21. Antitumor effects of the novel NF-kappaB inhibitor dehydroxymethyl-epoxyquinomicin on human hepatic cancer cells: analysis of synergy with cisplatin and of possible correlation with inhibition of pro-survival genes and IL-6 production.
    Poma P; Notarbartolo M; Labbozzetta M; Sanguedolce R; Alaimo A; Carina V; Maurici A; Cusimano A; Cervello M; D'Alessandro N
    Int J Oncol; 2006 Apr; 28(4):923-30. PubMed ID: 16525642
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Targeting NF-kappaB and induction of apoptosis by novel NF-kappaB inhibitor dehydroxymethylepoxyquinomicin (DHMEQ) in Burkitt lymphoma cells.
    Kimura N; Miyakawa Y; Kohmura K; Umezawa K; Ikeda Y; Kizaki M
    Leuk Res; 2007 Nov; 31(11):1529-35. PubMed ID: 17466373
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of a novel NF-kappaB inhibitor, dehydroxymethylepoxyquinomicin (DHMEQ), on growth, apoptosis, gene expression, and chemosensitivity in head and neck squamous cell carcinoma cell lines.
    Ruan HY; Masuda M; Ito A; Umezawa K; Nakashima T; Yasumatsu R; Kuratomi Y; Yamamoto T; Weinstein IB; Komune S
    Head Neck; 2006 Feb; 28(2):158-65. PubMed ID: 16355386
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A novel NF-κB inhibitor, dehydroxymethylepoxyquinomicin, ameliorates inflammatory colonic injury in mice.
    Funakoshi T; Yamashita K; Ichikawa N; Fukai M; Suzuki T; Goto R; Oura T; Kobayashi N; Katsurada T; Ichihara S; Ozaki M; Umezawa K; Todo S
    J Crohns Colitis; 2012 Mar; 6(2):215-25. PubMed ID: 22325176
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antitumor effect of a novel nuclear factor-kappa B activation inhibitor in bladder cancer cells.
    Horiguchi Y; Kuroda K; Nakashima J; Murai M; Umezawa K
    Expert Rev Anticancer Ther; 2003 Dec; 3(6):793-8. PubMed ID: 14686701
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Potent cytotoxic effect of a novel nuclear factor-kappaB inhibitor dehydroxymethylepoxyquinomicin on human bladder cancer cells producing various cytokines.
    Kodaira K; Kikuchi E; Kosugi M; Horiguchi Y; Matsumoto K; Kanai K; Suzuki E; Miyajima A; Nakagawa K; Tachibana M; Umezawa K; Oya M
    Urology; 2010 Apr; 75(4):805-12. PubMed ID: 20156648
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Lipopolysaccharide triggers macrophage activation of inflammatory cytokine expression, chemotaxis, phagocytosis, and oxidative ability via a toll-like receptor 4-dependent pathway: validated by RNA interference.
    Wu TT; Chen TL; Chen RM
    Toxicol Lett; 2009 Dec; 191(2-3):195-202. PubMed ID: 19735705
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The role of STAT1/IRF-1 on synergistic ROS production and loss of mitochondrial transmembrane potential during hepatic cell death induced by LPS/d-GalN.
    Lee HJ; Oh YK; Rhee M; Lim JY; Hwang JY; Park YS; Kwon Y; Choi KH; Jo I; Park SI; Gao B; Kim WH
    J Mol Biol; 2007 Jun; 369(4):967-84. PubMed ID: 17475277
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Control of allograft rejection by applying a novel nuclear factor-kappaB inhibitor, dehydroxymethylepoxyquinomicin.
    Ueki S; Yamashita K; Aoyagi T; Haga S; Suzuki T; Itoh T; Taniguchi M; Shimamura T; Furukawa H; Ozaki M; Umezawa K; Todo S
    Transplantation; 2006 Dec; 82(12):1720-7. PubMed ID: 17198266
    [TBL] [Abstract][Full Text] [Related]  

  • 30. DHMEQ, a novel NF-kappaB inhibitor, suppresses growth and type I collagen accumulation in keloid fibroblasts.
    Makino S; Mitsutake N; Nakashima M; Saenko VA; Ohtsuru A; Umezawa K; Tanaka K; Hirano A; Yamashita S
    J Dermatol Sci; 2008 Sep; 51(3):171-80. PubMed ID: 18406579
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Vitisin A suppresses LPS-induced NO production by inhibiting ERK, p38, and NF-kappaB activation in RAW 264.7 cells.
    Mi Jeong Sung ; Davaatseren M; Kim W; Sung Kwang Park ; Kim SH; Haeng Jeon Hur ; Myung Sunny Kim ; Kim YS; Dae Young Kwon
    Int Immunopharmacol; 2009 Mar; 9(3):319-23. PubMed ID: 19135555
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Inhibition of inducible nitric oxide synthase by Acanthopanax senticosus extract in RAW264.7 macrophages.
    Lin QY; Jin LJ; Cao ZH; Xu YP
    J Ethnopharmacol; 2008 Jul; 118(2):231-6. PubMed ID: 18486372
    [TBL] [Abstract][Full Text] [Related]  

  • 33. CT20126, a novel immunosuppressant, prevents collagen-induced arthritis through the down-regulation of inflammatory gene expression by inhibiting NF-kappaB activation.
    Lee SJ; Nam WD; Na HJ; Cho YL; Ha KS; Hwang JY; Lee H; Kim SO; Kwon YG; Kim YM
    Biochem Pharmacol; 2008 Jul; 76(1):79-90. PubMed ID: 18513703
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Dimethoxycurcumin, a synthetic curcumin analogue with higher metabolic stability, inhibits NO production, inducible NO synthase expression and NF-kappaB activation in RAW264.7 macrophages activated with LPS.
    Pae HO; Jeong SO; Kim HS; Kim SH; Song YS; Kim SK; Chai KY; Chung HT
    Mol Nutr Food Res; 2008 Sep; 52(9):1082-91. PubMed ID: 18481332
    [TBL] [Abstract][Full Text] [Related]  

  • 35. ERB-041, a selective ER beta agonist, inhibits iNOS production in LPS-activated peritoneal macrophages of endometriosis via suppression of NF-kappaB activation.
    Xiu-li W; Wen-jun C; Hui-hua D; Su-ping H; Shi-long F
    Mol Immunol; 2009 Jul; 46(11-12):2413-8. PubMed ID: 19447495
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of 5-O-Methylhirsutanonol on nuclear factor-kappaB-dependent production of NO and expression of iNOS in lipopolysaccharide-induced RAW264.7 cells.
    Han JM; Lee WS; Kim JR; Son J; Kwon OH; Lee HJ; Lee JJ; Jeong TS
    J Agric Food Chem; 2008 Jan; 56(1):92-8. PubMed ID: 18069795
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prevention of cancer cachexia by a novel nuclear factor {kappa}B inhibitor in prostate cancer.
    Kuroda K; Horiguchi Y; Nakashima J; Kikuchi E; Kanao K; Miyajima A; Ohigashi T; Umezawa K; Murai M
    Clin Cancer Res; 2005 Aug; 11(15):5590-4. PubMed ID: 16061877
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Anti-inflammatory activities of ent-16alphaH,17-hydroxy-kauran-19-oic acid isolated from the roots of Siegesbeckia pubescens are due to the inhibition of iNOS and COX-2 expression in RAW 264.7 macrophages via NF-kappaB inactivation.
    Park HJ; Kim IT; Won JH; Jeong SH; Park EY; Nam JH; Choi J; Lee KT
    Eur J Pharmacol; 2007 Mar; 558(1-3):185-93. PubMed ID: 17207792
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Withaferin A inhibits iNOS expression and nitric oxide production by Akt inactivation and down-regulating LPS-induced activity of NF-kappaB in RAW 264.7 cells.
    Oh JH; Lee TJ; Park JW; Kwon TK
    Eur J Pharmacol; 2008 Dec; 599(1-3):11-7. PubMed ID: 18838070
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Anti-inflammatory effects of sinapic acid through the suppression of inducible nitric oxide synthase, cyclooxygase-2, and proinflammatory cytokines expressions via nuclear factor-kappaB inactivation.
    Yun KJ; Koh DJ; Kim SH; Park SJ; Ryu JH; Kim DG; Lee JY; Lee KT
    J Agric Food Chem; 2008 Nov; 56(21):10265-72. PubMed ID: 18841975
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.